JP Morgan Maintains Overweight on Terns Pharmaceuticals, Raises Price Target to $44.5

Benzinga Newsdesk www.benzinga.com Positive 82.8%

Neg 0% Neu 0% Pos 82.8%

JP Morgan analyst Rodolfo Angele maintains Terns Pharmaceuticals (NASDAQ:TERN) with a Overweight and raises the price target from $44 to $44.5.